Enhancing Skin Cancer Early Detection and Treatment in Primary Care

Skin cancer screening may help find melanoma sooner, when it may be easier to treat. If found early melanoma and other types of skin cancer may be curable. Multi-component education may be an effective method to help primary care physicians (PCPs) learn about skin cancer screening. This clinical trial examines whether a clinician-focused educational intervention can improve PCP's knowledge and clinical performance to identify and triage skin cancer. This intervention may increase the PCP's ability to diagnose, treat and/or triage early-stage melanoma.

Study Overview

• Status: Completed
• Conditions: Cutaneous Melanoma
• Intervention / Treatment: Behavioral: Training and Education

Detailed Description

PRIMARY OBJECTIVE:

I. Evaluate whether a multi-component education strategy improves the ability of PCPs to identify and triage skin cancer.

OUTLINE:

Participants are assigned to 1 of 2 groups.

PCP participants complete group training. All training participants will also be offered series of short booster teaching points delivered virtually. Participants who complete the training also take part in pre-post knowledge assessments. PCP participants may also participate in a qualitative interview.

PCPs at the two clinics who do not receive the group training will serve as study comparators.

• Study Type: Interventional
• Enrollment (Actual): 54
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Oregon
    • Portland, Oregon, United States, 97239
      • OHSU Knight Cancer Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Clinicians at two Oregon Health & Science University (OHSU) primary care clinics will be invited to receive exposure to the melanoma early detection intervention
• Clinicians at the two clinics who do not receive the intervention will serve as study comparators
• These individuals are all aged 18 years or older
• All practice members speak English

Exclusion Criteria:

• No one will be intentionally excluded

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Comparison group; PCPs at the two clinics who do not receive the group training will serve as study comparators.
Experimental: Other, Pragmatic; PCP participants complete group training. All training participants will also be offered series of short booster teaching points delivered virtually. Participants who complete the training also take part in pre-post knowledge assessments. PCP participants may also participate in a qualitative interview.	Behavioral: Training and Education; Undergo group trainings

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Clinician Knowledge in Melanoma Risk and Lesion Identification	KnChange in melanoma risk, knowledge based upon survey questions prior to training and post-training. Content covered melanoma risk, knowledge of electronic health record tools specific to the training and lesion identification and biopsy procedure knowledge. A total score of correct responses for the 27 items was generated and transformed to represent the percent of correct items with zero being no correct items and 100% being all items correct. A change score from pre-training to post-training was generated where a positive change score represented the gain in knowledge in percent points and a negative change score representing a lower percent of correct responses from pre-training to post-training.	Immediately before and after the training session
Dermatology Referral	Mean percent of dermatology referrals per 1000 patients	minimum of 3 months and up to 1 year of EHR data for each clinician prior to the start of the training and the same months in the year post-training.
Use of Dermatology E-consults	number of dermatology e-consults	minimum of 3 months and up to 1 year of EHR data for each clinician prior to the start of the training and the same months in the year post-training.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Identification of suspicious lesions	Measured through EHR data.	3 months

Collaborators and Investigators

• Sponsor: OHSU Knight Cancer Institute
• Collaborators: National Cancer Institute (NCI); Oregon Health and Science University
• Investigators: Principal Investigator: Susan A Flocke, Ph.D., OHSU Knight Cancer Institute

Study record dates

Study Major Dates

• Study Start (Actual): April 25, 2023
• Primary Completion (Actual): June 30, 2024
• Study Completion (Actual): June 30, 2024

Study Registration Dates

• First Submitted: December 29, 2022
• First Submitted That Met QC Criteria: December 29, 2022
• First Posted (Actual): January 9, 2023

Study Record Updates

• Last Update Posted (Actual): December 8, 2025
• Last Update Submitted That Met QC Criteria: November 17, 2025
• Last Verified: June 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Neoplasms by Histologic Type; Skin Diseases; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neuroendocrine Tumors; Nevi and Melanomas; Skin Neoplasms; Skin and Connective Tissue Diseases; Melanoma; Socioeconomic Factors; Population Characteristics; Educational Status
• Other Study ID Numbers: STUDY00024809 (Other Identifier: OHSU Knight Cancer Institute); NCI-2022-09484 (Registry Identifier: CTRP (Clinical Trial Reporting Program)); P50CA244289 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: No plan is needed

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No